Thiotepa-busulfan-fludarabine (tbf) ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Thiotepa-busulfan-fludarabine (tbf) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the chronic malignancies working party of the ebmt
Auteur(s) :
Battipaglia, Giorgia [Auteur]
Mauff, Katya [Auteur]
Wendel, Lotus [Auteur]
Angelucci, Emanuele [Auteur]
Mohty, Mohamad [Auteur]
Centre de Recherche Saint-Antoine [UMRS893]
Arcese, William [Auteur]
Santarone, Stella [Auteur]
Rubio, Marie-Thérèse [Auteur]
Ingénierie Moléculaire et Physiopathologie Articulaire [IMoPA]
Krger, Nicolaus [Auteur]
Fox, Maria Laura [Auteur]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Iori, Anna Paola [Auteur]
Fanin, Renato [Auteur]
Chalandon, Yves [Auteur]
Pioltelli, Pietro [Auteur]
Marotta, Giuseppe [Auteur]
Chiusolo, Patrizia [Auteur]
Sever, Matjaz [Auteur]
Solano, Carlos [Auteur]
Contentin, Nathalie [Auteur]
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen [CLCC Henri Becquerel]
De Wreede, Liesbeth C. [Auteur]
Czerw, Tomasz [Auteur]
Hernandez-Boluda, Juan Carlos [Auteur]
Hayden, Patrick J. [Auteur]
Mclornan, Donal P. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Mauff, Katya [Auteur]
Wendel, Lotus [Auteur]
Angelucci, Emanuele [Auteur]
Mohty, Mohamad [Auteur]
Centre de Recherche Saint-Antoine [UMRS893]
Arcese, William [Auteur]
Santarone, Stella [Auteur]
Rubio, Marie-Thérèse [Auteur]
Ingénierie Moléculaire et Physiopathologie Articulaire [IMoPA]
Krger, Nicolaus [Auteur]
Fox, Maria Laura [Auteur]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Iori, Anna Paola [Auteur]
Fanin, Renato [Auteur]
Chalandon, Yves [Auteur]
Pioltelli, Pietro [Auteur]
Marotta, Giuseppe [Auteur]
Chiusolo, Patrizia [Auteur]
Sever, Matjaz [Auteur]
Solano, Carlos [Auteur]
Contentin, Nathalie [Auteur]
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen [CLCC Henri Becquerel]
De Wreede, Liesbeth C. [Auteur]
Czerw, Tomasz [Auteur]
Hernandez-Boluda, Juan Carlos [Auteur]
Hayden, Patrick J. [Auteur]
Mclornan, Donal P. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Titre de la revue :
Bone Marrow Transplantation
Nom court de la revue :
Bone Marrow Transplant
Numéro :
56
Pagination :
1593–1602
Date de publication :
2021-02-01
ISSN :
1476-5365
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option in MF. There is no consensus on the optimal conditioning regimen. We report outcomes of 187 patients with MF transplanted between ...
Lire la suite >Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option in MF. There is no consensus on the optimal conditioning regimen. We report outcomes of 187 patients with MF transplanted between 2010 and 2017 conditioned with TBF. Median age was 58 years. Median interval from diagnosis to allo-HCT was 44 months. Donors were haploidentical (41%), unrelated (36%) or HLA-identical siblings (23%). Stem cell source was PB in 60%. Conditioning was myeloablative in 48% of cases. Antithymocyte globulin (ATG) was used in 41% of patients. At 100 days, neutrophil and platelet engraftment were 91% and 63% after a median of 21 and 34 days, respectively. Grade II-IV and III-IV acute GVHD occurred in 24% and 12%, while at 3 years, all grade chronic GVHD and chronic extensive GVHD had been diagnosed in 38% and 11%. At 3 years, OS, RFS and GRFS were 55%, 49% and 43%, respectively. RI and NRM were 17% and 33%. On multivariate analysis, poor KPS and the use of unrelated donors were associated with worse GRFS and a higher grade II-IV acute GVHD, respectively. Neither donor type nor intensity of the conditioning regimen influenced survival outcomes. TBF is a feasible conditioning regimen in allo-HCT for MF in all donor settings although longer term outcomes are required.Lire moins >
Lire la suite >Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option in MF. There is no consensus on the optimal conditioning regimen. We report outcomes of 187 patients with MF transplanted between 2010 and 2017 conditioned with TBF. Median age was 58 years. Median interval from diagnosis to allo-HCT was 44 months. Donors were haploidentical (41%), unrelated (36%) or HLA-identical siblings (23%). Stem cell source was PB in 60%. Conditioning was myeloablative in 48% of cases. Antithymocyte globulin (ATG) was used in 41% of patients. At 100 days, neutrophil and platelet engraftment were 91% and 63% after a median of 21 and 34 days, respectively. Grade II-IV and III-IV acute GVHD occurred in 24% and 12%, while at 3 years, all grade chronic GVHD and chronic extensive GVHD had been diagnosed in 38% and 11%. At 3 years, OS, RFS and GRFS were 55%, 49% and 43%, respectively. RI and NRM were 17% and 33%. On multivariate analysis, poor KPS and the use of unrelated donors were associated with worse GRFS and a higher grade II-IV acute GVHD, respectively. Neither donor type nor intensity of the conditioning regimen influenced survival outcomes. TBF is a feasible conditioning regimen in allo-HCT for MF in all donor settings although longer term outcomes are required.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Date de dépôt :
2021-07-06T12:44:46Z
2024-01-23T14:21:48Z
2024-01-23T14:21:48Z